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Hereditary spastic paraplegia (HSP) is considered one of the most heterogeneous groups of neurological disorders, both clinically and
genetically. The disease comprises pure and complex forms that clinically include slowly progressive lower-limb spasticity resulting
from degeneration of the corticospinal tract. At least 48 loci accounting for these diseases have been mapped to date, and mutations
have been identified in 22 genes, most of which play a role in intracellular trafficking. Here, we identified mutations in two functionally
related genes (DDHD1 andCYP2U1) in individuals with autosomal-recessive forms of HSP by using either the classical positional cloning
or a combination of whole-genome linkage mapping and next-generation sequencing. Interestingly, three subjects with CYP2U1muta-
tions presented with a thin corpus callosum, white-matter abnormalities, and/or calcification of the basal ganglia. These genes code for
two enzymes involved in fatty-acidmetabolism, and we have demonstrated in human cells that the HSP pathophysiology includes alter-
ation of mitochondrial architecture and bioenergetics with increased oxidative stress. Our combined results focus attention on lipid
metabolism as a critical HSP pathway with a deleterious impact on mitochondrial bioenergetic function.Introduction
Hereditary spastic paraplegia (HSP), also known as Stru¨m-
pell-Lorrain disease, is recognized as one of the most clin-
ically and genetically heterogeneous groups of inherited
neurodegenerative disorders. These disorders are mainly
characterized by slowly progressive lower-limb spasticity
that worsens over time. The symptoms are the conse-
quence of corticospinal-tract degeneration.1–3 Affected
subjects are clinically classified according to the absence
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The American Joucomplex HSP) of additional neurological or extraneurolog-
ical signs. This clinical heterogeneity partially underlies
the large genetic heterogeneity of this group of disorders;
at least 48 loci have been mapped to date and account
for all classical modes of inheritance.4,5 So far, mutations
have been identified in 22 genes,5 most of which play
a role in intracellular trafficking.6–8
Autosomal-recessive HSP (AR-HSP) is less common than
the autosomal-dominant form, except in countries with
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disease can be due to mutations in SPG5/CYP7B1 (MIM
603711), SPG7/PGN (MIM 602783), and SPG30/KIF1A
(MIM 601255) or can be linked to SPG28 (MIM
609340).11–15 Mutations in SPG11/KIAA1840 (MIM
610844) account for ~20% of the autosomal-recessive
(AR) forms,16 but many genes remain to be discovered
given that 60% of AR-HSP is still genetically unex-
plained.5
Here, we report the identification of causative mutations
in two genes after the use of next-generation sequencing
focused on all exons of the SPG28 interval, as well as
linkage mapping combined with systematic candidate-
gene analysis in SPG49, identified in this study. These
combined approaches enabled us to identify in individuals
from three families four truncating mutations in DDHD1
(MIM 614603), encoding for a phosphatidic-acid (PA)-
preferring phospholipase A1. In subjects from five different
families, we also found five mutations in CYP2U1 (MIM
610670), encoding a P450 hydroxylase. We demonstrate
in human cells that the pathophysiology of SPG28 and
SPG49 includes alteration of mitochondrial architecture
and bioenergetics with increased oxidative stress.Subjects and Methods
Subjects
Ninety-nine index individuals from families affected by AR-HSP
and without identified mutations in SPG11, SPG5, and SPG7,
were included in this study and originated mainly from France,
Italy, the Middle East, and North Africa. This study was approved
by the local Bioethics Committee (approval number 03-12-07
from the Comite´ Consultatif pour la Protection des Personnes et
la Recherche Biome´dicale Paris-Necker to A. Durr and A. Brice).
Written informed consent was signed by all index persons and
by 39 additional participating members of the families before
blood samples were collected for DNA extraction. All clinical eval-
uations included a full medical history and examination, estima-
tion of the age of onset, observation of additional neurological
signs, electroneuromyographic studies, and, when possible, brain
MRI and/or computed-tomography (CT) scans.
Next-Generation Sequencing in Family FSP445
After exclusion of large genomic rearrangements in the SPG28
linkage interval by comparative genomic hybridization (CGH) in
subjects FSP445-V.3 and FSP445-V.1 by chromosome-14-specific
385K NimbleGen arrays (data not shown), targeted enrichment
and next-generation sequencing were performed on the DNA of
individual FSP445-V.3 from the original SPG28-affected family.11
Enrichment of all 723 exons in chr14: 49,100,775–55,305,189
was performed by hybridization of shotgun fragment libraries to
a custom Roche NimbleGenmicroarray according to the manufac-
turer’s recommendations. Threemicrograms of amplified enriched
DNA was used as input for massively parallel sequencing on
a Roche 454-GS-FLX sequencer with Titanium reagents. Sequence
data were then aligned with hg18 human genome as a reference.
In total, 285,704 reads were obtained with an average length of
399 bp; 283,483 (99%) of those reads could be mapped, and
68% of them were on target. From the total of 723 enriched
regions, 689 (95%) were covered entirely, and 99% of targeted1052 The American Journal of Human Genetics 91, 1051–1064, Decebases were covered at least 103 (95% of all captured exons were
covered entirely). The real coverage of enriched regions was
803. Variants with fewer than three reads or accounting for less
than 25% of all reads were excluded from the analysis. A total of
1,062 variations were identified. We excluded known validated
SNPs present in dbSNP and the HapMap database. As expected,
88 of the remaining 239 variants were homozygous in this disease:
17 were intergenic, 63 were intronic, and 8, including 2 exonic
variants, were in the mRNA.
Genome-wide Scan in Family FSP719
Exclusion of linkage to some of the most common AR-HSP-
associated loci (SPG5, SPG15 [MIM 270700], SPG24 [MIM
607584], SPG28, SPG30, and SPG32 [MIM 611252]) and of muta-
tions in SPG7 and SPG11 was performed prior to this study (data
not shown).
A genome scan with 6,090 SNP markers (LINKAGE_V panel,
Illumina) covering all chromosomes was performed on family
FSP719. Genotypes were generated with BeadStudio software
(Illumina) and analyzed with MERLIN 1.0,17 and all family
members were considered. An AR inheritance, a penetrance of
95% without phenocopy, a disease allele frequency of 0.00001,
equal allele frequencies for each marker, and equal male-female
recombination rates were considered.
Linked and uninformative regions were explored by genotyping
of 47 additional microsatellite markers in all family members. PCR
amplicons were resolved on an ABI 3730 sequencer with the use
of fluorescent primers, and the results were analyzed with
GeneMapper 4 (Applied Biosystems). We manually constructed
haplotypes by minimizing the number of recombination events.
Genetic distances were taken from the MAP-O-MAT consortium.
Candidate-Gene Analysis
After exclusion of large genomic rearrangements by CGH in one
person of SPG49-linked family FSP1015 (data not shown), all
coding exons of genes in the SPG49 candidate interval, including
flanking splicing sites and at least 50 bp of intronic sequence on
each side,were analyzedbydirect sequencing (primers are available
from the authors upon request) with BigDye Chemistry (Applied
Biosystems). The sequence products were run on an ABI 3730
sequencer, and electrophoretic profiles were compared with the
reference hg18 sequence with the use of SeqScape 2.5 (Applied
Biosystems).
Mutation screening of DDHD1 (RefSeq accession number
NM_030637.2; hg19) and CYP2U1 (RefSeq NM_183075.2; hg19)
was performed in 96 index cases by classical Sanger sequencing
(primers and PCR conditions are available upon request).
The effects of mutations and amino acid conservation in other
species were analyzed with ALAMUT 2.2 (Interactive Biosoftware),
PolyPhen-2, and MutationTaster.18,19
Rearrangement Analysis
Exon deletions or duplications in CYP2U1 and DDHD1 were
explored by quantitative multiplex PCR of short fragments
(QMPSF; primers and PCR conditions are available from the
authors upon request) and analyzed with GeneMapper 4.
Investigation of Mitochondrial Energetics and
Oxidative Stress
The mitochondrial respiratory rate was measured in lym-
phocytes and fibroblasts grown in RPMI 1640 medium andmber 7, 2012
DMEM, respectively, both of which contained 5 mM glucose and
2 mM glutamine (Glutamax) supplemented with 10% fetal
bovine serum (PAA), 100 U/ml penicillin, and 100 U/ml of
streptomycin. All experiments were performed with the same
number of flask divisions in culture between cases and controls.
For the lymphoblast cells (nonadherent), respiration was
measured in real time on 1 3 106 cells per ml by polarography,
with the use of the Hansatech Oxygraph system (Oxy 1,
Hansatech), at 37C in growth medium containing glucose and
glutamine as energy substrates. We assessed respiratory coupling
by adding oligomycin, a specific inhibitor of mitochondrial
F1F0-ATPsynthase, in the cuvette of the oxygraph. The coupl-
ing of mitochondrial respiration with ADP phosphoryla-
tion was evaluated by the ratio of the routine respiratory rate to
the rate measured in the presence of oligomycin (at steady
state). Respiration was expressed as ngatom O per min per one
million cells. Each cell culture was assayed at least three
times (minimum of three different cultures according to the
sample). For the fibroblasts, respiration was assayed on 96-well
plates with the extracellular flux analyzer XF96 (Seahorse
Bioscience).
The amount of mitochondria was compared on protein extracts
from lymphoblastoid cell lines by immunoblot analysis according
to standard procedures20 and by labeling of actin C4 (Abcam,
1/1,000) and TOM20 (BD Biosciences, 1/1,000). The total cellular
ATP content and the mitochondrial contribution to cellular ATP
production were measured by bioluminescence with the ATP
Roche assay Kit II on 1 3 106 cells as described elsewhere.21 The
concentration of reactive oxygen species was measured with
the CMH2DCFDA fluorescent probe on a fluorometer (SAFAS) as
previously reported.21
The measurement of respiratory-chain-enzyme activities was
performed spectrophotometrically with standardized techniques
as described previously.22 In brief, fibroblasts and lymphoblasts
of affected and control subjects were grown in DMEM or RPMI
and harvested at 70% confluency. We performed cell- and mito-
chondrial-membrane disruption by freezing the cells in liquid
nitrogen, thawing them at room temperature, and subsequent
sonication. Total protein content was measured with the bicin-
choninic acid assay, and maximal activities of respiratory-chain
complex I (NADH: ubiquinone oxidoreductase), complex II
(succinate dehydrogenase), complex III (ubiquinol cytochrome
c reductase), and complex IV (cytochrome c oxydase) were
assayed at 30C and expressed as nmol/min/mg of protein. Mito-
chondrial transmembrane electric potential (Dc) was measured
on a fluorometer (SAFAS Xenius) with the potentiometric dye
tetramethylrhodamine methyl esther (TMRM) obtained from
Invitrogen as previously detailed.23mRNA-Expression Analysis
Total RNA was extracted from various tissues and different devel-
opment stages of four wild-type c57bl6 mice with the RNeasy
Mini kit (QIAGEN) and was used for generating cDNA with the
Superscript III First-Strand Synthesis SuperMix for quantitative
RT-PCR (Invitrogen). Real-time quantitative expression analysis
of DDHD1, CYP2U1, and RAD51 (control [MIM 179617]) was per-
formed on a Roche LC480-1536 with QIAGEN Quantitect primer
assays in triplicate. Expression levels relative to PGK1 (MIM
311800) or PP1A, used as reference genes, were determined with
qbase Plus software (Biogazelle) and were then compared with
the Pearson test.The American JouIn lymphoblasts from individuals FSP445-4 and FSP445-6, we
analyzed the effect on mRNA splicing of a variant affecting the
last codon of exon 7 of DDHD1 and predicted to alter splicing
by the Splice Site Prediction by Neural Network. This was done
on polyAþ RNA that was reversely transcribed with the 1st Strand
cDNA Synthesis Kit (Roche) according to the manufacturer’s
random primer protocol and was followed by subcloning and
direct sequencing of the PCR products with specific primers (avail-
able upon request).Overexpression Analysis
HeLa cells used for transient transfection of the CYP2U1 cDNA
fused to green fluorescent protein (GFP) (Origen) were maintained
in DMEM (Invitrogen) supplemented with fetal calf serum and
antibiotics (100 UI/ml penicillin and 100 mg/ml streptomycin).
Cells (10,000 cells per well) were transfected with the use of
Fugene Xtreme Gene according to the manufacturer’s instructions
(Promega). After 48 hr, cells were fixed with 4% paraformalde-
hyde, washed, permeabilized with 0.25% Triton/PBS, blocked
for 1 hr with 10% normal goat serum (NGS) before being incu-
bated for 1 hr with primary antibodies at room temperature in
3% NGS/PBS, and then washed in PBS and incubated for
45 min with secondary antibodies in 3% NGS/PBS. Cultures
were mounted with Vectashield HardSet Mounting Medium
(Eurobio) or counterstained with DAPI (1 mg/ml, Sigma) and
mounted with Fluoromount-G (Southern Biotech). Immunocyto-
chemistry was performed with the following primary antibodies:
rabbit anti-SDHA (Abcam), anti-Calregulin (Santa Cruz Biotech-
nology), and mouse anti-FLAG (Sigma). Secondary antibodies
were alexa-fluor 568 and 647 (Invitrogen) anti-mouse and anti-
rabbit. Images of CYP2U1 overexpression were acquired with
a Zeiss VivaTome microscope with a 603 objective. AxioVision
software (Zeiss) was used for analyzing one stack for visualizing
the colocalization. For quantitative colocalization analysis of
CYP2U1 with mitochondria or endoplasmic reticulum (ER), all
images were processed identically with MBF Image J software
and were quantified with Intensity Correlation Analysis plug-in
(ICA) as defined elsewhere.24 For each stack, similar background
signal was subtracted, and images were analyzed as a z-series
projection taken in intervals 0.2 mm deep. Two coefficients
were calculated for each cell: (1) Rr is the Pearson’s correlation
coefficient and ranges from 1 to þ1 (a value of 1 represents
perfect correlation, 1 represents perfect exclusion, and 0 repre-
sents random localization) and (2) ICQ is the intensity correlation
quotient in which colocalization is defined as the synchronous
increase or decrease in fluorescence intensities.24,25 The ICQ is
based on the nonparametric sign-test analysis of the PDM
(product of the differences from the mean) values and is equal
to the ratio of the number of positive PDM values to the total
number of pixel values. The ICQ values are distributed
between 0.5 and þ0.5 (0.5 represents a random staining,
and þ0.5 represents perfect overlap). Each experiment was per-
formed on three independent cells preparations, and 25–30 cells
were quantified for each condition.
Fibroblasts were transfected with a pCMV/mito/GFP vector
(Invitrogen) in which the Myc epitope was deleted26 with the
use of the Neon system (Invitrogen) according to the manufac-
turer‘s instructions. Twenty four hours after transfection, live cells
were observed on a Zeiss Axiovert 200 inverted video-microscope
with a 633 oil objective. Metamorph 7.7.7.0 software was used for
acquiring the image.rnal of Human Genetics 91, 1051–1064, December 7, 2012 1053
Figure 1. Mutations in DDHD1
(A–C) Family trees and segregation analysis of the mutations identified in families FSP445 (A), THI26002 (B) and FSP375 (C). Squares
represent males, circles represent females, diamonds indicate anonymized subjects, filled symbols represent affected individuals, and
a double line indicates consanguinity. The following abbreviations are used: M, mutation; þ, wild-type; and *, sampled individuals.
The electrophoregrams are shown in Figure S2.
(D) A graphical representation of DDHD1 (RefSeq NM_030637.2) on chromosome 14 indicates the DDHD domain (gray boxes) and the
location of the mutations (c.1249C>T [p.Gln417*], c.1766G>A [p.Arg589Gln; r.spl?], c.1874delT [p.Leu625*], and c.2438-1G>T [r.spl?])
(arrows). Black and white boxes represent coding and noncoding exons, respectively. The DDHD1 transcript is 5,603 bp long and is
composed of 12 exons that encode an 872 amino acid protein. There are three known isoforms of DDHD1; isoforms b and c are longer
than isoform a because they include an alternate in-frame coding exon (white box). The sequence contains a lipase consensus domain
and also includes a putative coiled-coil-forming region and a DDHD domain between residues 611 and 858 of isoform a; the four
conserved residues that can form ametal binding site are seen in phosphoesterase domains. This domain is found in retinal degeneration
B proteins, as well as in a family of probable phospholipases.Results
Identification of Mutations in SPG28/DDHD1
We previously described a consanguineous Moroccan
family (with AR inheritance) in which we mapped the
disease locus, SPG28, to chromosome 14q.11We sequenced
all exons of the SPG28 interval in one affected subject
(FSP445-V.3) from the original SPG28-affected kindred by
using a custom Roche-NimbleGen Capture assay and
massively parallel sequencing on a Roche 454-GS-FLX
sequencer. From 239 variants identified, we focused our
analysis on the two homozygous exonic variants not re-
ported as polymorphisms: (1) the c.427G>T (p.Ala143Ser)
transversion in SAMD4A (MIM 610747; RefSeq
NM_015589.4), encoding SMAUG1, an RNA-binding
protein involved in mRNA silencing and deadenyla-
tion in postsynaptic densities, and (2) the c.1766G>A
(p.Arg589Gln) variant located in the last nucleotide of
exon 7 of DDHD1 (encoding an enzyme of lipid metabo-
lism) and affecting correct DDHD1 mRNA splicing (Fig-
ure 1A, Figures S1 and S2, and Table S1, available online).
These two variants cosegregated with the disease and were
absent in controls. The deleterious nature of the DDHD11054 The American Journal of Human Genetics 91, 1051–1064, Decemutation let us focus on this gene. Further screening of
all DDHD1 coding exons by Sanger sequencing and
QMPSF in 96 index cases affected byHSPwith an unknown
genetic cause identified mutations absent in controls in
two individuals (Figures 1B and 1C, Figure S2, and Table
S1). One simplex French case (FSP375-II.1) harbored
heterozygous mutations c.1249C>T (p.Gln417*) and
c.2438-1G>T in exon 4 and intron 11, respectively. DNA
of relatives or mRNA was not available, so we could not
exclude that the mutations were in cis, although this is
unlikely given their rarity (Table S1). One Turkish boy
and his affected brother harbored the homozygous
c.1874del (p.Leu625*) mutation, which was also present
at the heterozygous state in their healthy parents.
Clinical data from the three additional SPG28-affected
subjects identified in this study extended the clinical spec-
trum of this disease compared to the pure phenotype origi-
nally described.11 When examined at 30 years of age, the
twoTurkishbrothers showedprogressive spastic gait (which
had been developing since adolescence), and one had a
cerebellar oculomotor disturbance with saccadic eye pur-
suit. No other signs were noticed, and brain and spineMRI,
sensory-evoked potentials (tibial nerve and median nerve),mber 7, 2012
and nerve-conduction studies were normal. The French
SPG28-affectedwoman, aged 62 years at her latest examina-
tion, had suffered since infancy from HSP with axonal
neuropathy but had unremarkable spinal and brain MRI.
Mapping of an AR-HSP-Associated Locus, SPG49
A genome scan with the Illumina LINKAGE Mapping V
SNP Set was performed in family FSP719, composed of
two nuclear consanguineous kindreds from Saudi Arabia.
Multipoint linkage analysis (Figure S3A) identified on
chromosomes 4, 19, and X three genomic regions with
uninformative multipoint LOD scores between 0 and þ1;
these regions were later excluded with the use of 23 addi-
tional markers (data not shown). A fourth region of 34
consecutive SNPs on chromosome 4 presented a significant
multipoint LOD score of þ3.97 between markers
rs1528381 and rs1525760. Further genotyping of 24 addi-
tional microsatellite markers and haplotype reconstruc-
tions restricted the region and confirmed a 5.9 Mb (6.29
cM) region of homozygosity by descent between markers
D4S3256 and D4S2309 in all four affected individuals of
the family (Figure S4). A maximum and significant multi-
point LOD score of þ4.76 was then reached (Figure S3B).
This locus was named SPG49 according to the Human
Genome Organization. A second Saudi Arabian AR-HSP-
affected family was found to be linked to this locus
with a multipoint LOD score of þ2.4. Both families shared
a portion of the same homozygous haplotype, suggesting
a common ancestry and narrowing down the SPG49 candi-
date interval to the 3.8 Mb (4.42 cM) between markers
D4S3256 and D4S2940 (Figure S4).
Identification of Mutations in SPG49/CYP2U1
In all coding exons of the 23 genes assigned to the SPG49
region, we identified a single CYP2U1 variant, c.947A>T
(p.Asp316Val), which segregated with the disease at the
homozygous state in the two SPG49-affected families
(Figure 2A and Figure S2) and was not detected in healthy
controls (Table S1). This variant affected an amino acid
highly conserved during evolution among orthologs of
CYP2U1 (Figure 2B) but also among other cytochrome
P450 proteins (data not shown), including CYP7B1
(SPG5).15 The mutation was localized in the cytochrome
P450 functional domain and was predicted to be
damaging.18,19 Sanger sequencing and QMPSF analysis
of all exons of CYP2U1 in 94 index cases affected by
HSP with an undetermined genetic basis identified four
mutations predicted to be damaging and absent in
controls (Figures 2C–2E, Figure S2, and Table S1). A homo-
zygous missense mutation affecting a conserved amino
acid (c.1139A>G [p.Glu380Gly]) was detected in an
Italian simplex case (ITAP9-II.1) with suspected consan-
guinity. A homozygous 13 bp deletion (in exon 1) leading
to a frameshift (c.61_73del [p.Leu21Trpfs*19]) segre-
gated with the disease in two Egyptian brothers (from
family HSP1363). Finally, two heterozygous mutations
(c.784T>C [p.Cys262Arg] and c.1462C>T [p.Arg488Trp])The American Jousegregated in trans in two siblings with Spanish and
Vietnamese ancestry.
Phenotype Associated with the SPG49 Clinicogenetic
Entity
The overall SPG49 phenotype (Table 1) was an early-onset
(2.55 2.5 SD years; range ¼ birth to 8 years) spastic para-
plegia frequently involving the upper limbs (7/11 cases)
and rarely associated with dystonic postures (n ¼ 2) and
cognitive alterations (n ¼ 3). Among eight tested subjects,
all had normal conduction velocities of the median and
peroneal nerves, but the facts that five of them had a slight
reduction in the amplitude of compound muscle action
potentials and that three of them had a reduction in the
amplitude of sensory-nerve action potential indicate the
presence of infraclinical axonal neuropathy, predomi-
nantly in the lower limbs (data not shown). On brain
MRI, thinning of the corpus callosum (n ¼ 1) and white-
matter lesions (3/8) were observed but were not inaugural
MRI features in two affected subjects (Figure S5). Interest-
ingly, globus pallidus hypointensities were detected during
follow-up analysis of two siblings and were confirmed
as calcifications by CT scans; they were reminiscent of
the familial idiopathic basal-ganglia calcification (Fahr
syndrome) (see GeneReviews inWeb Resources). Therefore,
SPG49 can be added to the growing number ofmixed forms
(pure and complex) of HSP, such as SPG5 or SPG7.12,13 The
severity of symptoms varied widely among affected sub-
jects, even in the same family, and independently of the
nature of the mutation; two individuals (FSP719-V.5 and
HSP1363-IV.4) never walked, and a third (FSP719-IV.3)
was limited in his running capacities, although he had
otherwise fully conserved autonomy at 30 years of age.
Expression Profiles of CYP2U1 and DDHD1 mRNA
DDHD1 andCYP2U1 transcripts have been shown to be ex-
pressed in the brain.27–29 To identify a possible relationship
between these two genes, we explored their expression pro-
files in multiple CNS and non-CNS mouse tissues by quan-
titative RT-PCR. We observed that DDHD1 and CYP2U1
mRNA levels increased during development in all tested
tissues, including the cerebral cortex, but not in peripheral
tissues in the case of DDHD1 (Figure S6). Moreover, we
showed that their expression levels were significantly core-
gulated at the embryonic and adult stages in the CNS (Fig-
ure S6), but not innon-neuronal tissues, a result compatible
with a concomitant need for the two proteins in the CNS.
Subcellular Localization of CYP2U1 and DDHD1 and
Exploration of Mitochondrial Functions and Network
Organization
We then investigated how these mutations affect cell phys-
iology in HSP. At a subcellular level, DDHD1 fused with a
FLAG tag displayed a diffuse distribution pattern almost
exclusively in the cytosol (data not shown), but it has also
been observed partially in microsomes and mitochon-
dria.30Becauseof its PLA1activity,DDHD1must transientlyrnal of Human Genetics 91, 1051–1064, December 7, 2012 1055
Figure 2. CYP2U1 Mutations in SPG49-Affected Subjects
(A) Segregation analysis of the c.947A>T mutation in two Saudi Arabian families. Their corresponding electrophoregrams are in
Figure S2.
(B) Conservation of the amino acids affected by missense variations with the use of ALAMUT software.
(C–E) Pedigrees and segregation ofmutations in AR-HSP-affected families HSP1363 (C), ITAP9 (D), and FSP544 (E). A T1-weighted sagittal
cerebral MRI from individual HSP1363-IV.4 shows a thin corpus callosum (C, red arrow). A CT scan of individual FSP544-III.1 (E, top
view) shows bilateral globus pallidus calcifications (E, green arrow), and a brain MRI (E, bottom view) shows white-matter abnormalities
(E, blue arrow), including the ‘‘ear of the lynx’’ aspect of frontal horns of the lateral ventricles (E, orange arrow).
(F) Schematic representation of CYP2U1 (coding exons are represented by blue boxes). The locations of the identified mutations
(c.61_73del [p.Leu21Trpfs*19], c.784T>C [p.Cys262Arg], c.947A>T [p.Asp316Val], c.1139A>G [p.Glu380Gly], and c.1462C>T
[p.Arg488Trp]) are shownwith red arrows, and the cytochrome P450 domain is indicated by red boxes. The five exons of CYP2U1 (RefSeq
NM_183075.2) cover 1,635 bp and encode a 544 amino acid protein with potential transmembrane domains and a heme binding site in
the cytochrome P450 domain.interact withmembranes from the cytosolic pool to process
its substrates. We also showed that CYP2U1 fused with
enhanced GFP partially colocalized with ER andmitochon-
dria (Figure S7), as previously reported.31
Given the partial mitochondrial localization of both
proteins and the implication of this organelle in other
HSPs,12,32 we investigatedmitochondrial functions in lym-
phoblasts. At steady state in growth medium, the mean
routine respiration was significantly lower in SPG49 and
SPG28 cells than in controls (Figure 3A; controls versus
SPG49: p ¼ 0.053, which is very close to the limit of sig-1056 The American Journal of Human Genetics 91, 1051–1064, Decenificance; controls versus SPG28: p ¼ 0.011). No cell death
was observed (trypan-blue staining and count), suggesting
that mitochondrial alterations were not a consequence
of a reduction in cell viability. As expected from the res-
piratory data, total and mitochondrial ATP contents were
significantly reduced in SPG49 and SPG28 lymphoblasts
(Figure 3B). Furthermore, a concomitant increase of the
concentration of cytosolic hydrogen peroxide as mea-
sured by CM-H2DCFDA fluorescence (Figure 3C) was also
observed in SPG49 and SPG28 cells when compared to
controls. No major difference in mitochondrial content,mber 7, 2012
Table 1. Clinical Phenotypes in 11 SPG49-Affected Individuals
SPG49-Affected Subject
FSP719-IV.3 FSP719-V.2 FSP719-V.3 FSP719-V.5 FSP1015-IV.2 FSP1015-IV.3 HSP1363-IV.1 HSP1363-IV.4 ITAP9-II.1 FSP544-II-1 FSP544-II-2
Gender male female female female female male male male male female male
Age (years) 33 21 18 11 25 21 12 5 31 29 27
Duration of
follow up (years)
3 12 13 10 12 13 2 2 4 9 9
Age at onset 3 years 5 years 1.5 years 8 months birth 5 years 1.5 years birth 8 years 13 months 16 months
Symptoms at
onset
delayed
walking,
spastic gait
unsteadiness,
spastic gait
delayed
walking,
unsteadiness
delayed
walking,
spasticity
delayed
walking,
toe walking
toe walking unsteady gait,
tip-toe walking
spasticity since
birth
cannot run,
frequent falls
delayed walking,
spastic gait
spastic gait
Age at walking 3 years 1.5 years 1.5 years never walked 6 years (after
surgery)
1 year 2 years never walked 2 years delayed normal
Cognitive delay
or mental
retardation
no no no yes no no no no speech no yes yes
Lower-limb
hyperreflexia and
positive extensor
response (Babinski)
yes yes yes yes yes yes yes yes yes yes yes
Upper-limb
hyperreflexia
no no no yes yes yes no yes yes yes yes
Dysarthria no no no no no no no no speech no yes, mild yes, mild
Extrapyramidal
signs
no no no dystonia in
upper limbs
no no no dystonia in
upper limbs
no no no
Other signs no no no no no no no no no maculopathy no
Disability stagea
(at age)
2 (30 years) 2 (21 years) 2 (18 years) 6 (11 years) 5 (25 years) 2 (21 years) 4 4 2 (28 years) 6 (16 years) 5
MRI cerebral
(at age)
ND normal
(20 years)
normal
(17 years)
normal
(10 years)
ND ND; CT
normal
normal
(5 years)
TCC, WMLs,
mild cortical
changes
(2.5 years)
normal
(28 years)
normal (14 years),
then WMLs and
globus pallidus
hypointensities
(26 years)
WMLs and
globus pallidus
hypointensities
(26 years)
MRI of spine
(at age)
ND normal
(20 years)
normal
(17 years)
normal
(10 years)
ND normal normal (4 years) ND normal
(28 years)
normal normal
(19 years)
Nerve-conduction
studies (at age)
ND subclinical
axonal
neuropathy
(21 years)
subclinical
axonal
neuropathy
(18 years)
subclinical
axonal
neuropathy
(10 years)
subclinical
axonal
neuropathy
(25 years)
subclinical
axonal
neuropathy
(21 years)
normal normal normal
(28 years)
ND ND
None of the affected persons presented with muscle wasting, dysphagia, cerebellar signs, superficial sensory loss, or auditory loss. Muscle biopsy in one subject was unremarkable. The following abbreviations are used: CT,
computed tomography; ND, not done; TCC, thin corpus callosum; and WML, white-matter lesion.
aDisability scale: 1, minimal disability (slight stiffness of the legs); 2, mild disability (unable to run but full autonomy); 3, moderate disability in walking (reduced perimeter and frequent falls); 4, severe disability (unilateral
assistance required for walking); 5, bilateral assistance required for walking; 6, wheelchair bound; and 7, bedridden.
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Figure 3. Mitochondrial Dysfunctions in Lymphoblasts from
SPG28- and SPG49-Affected Individuals
(A) Mitochondrial respiration rate in SPG28-affected subjects
(FSP445-V.3 [SPG28-1] and FSP445-V.1 [SPG28-2] aged 44 and
42 years, respectively, at sampling), SPG49-affected subjects
(FSP719-V.3 [SPG49-1] and FSP1015-IV.3 [SPG49-2] aged 18 and
21 years, respectively, at sampling), and three control lymphoblas-
toid cell lines (aged 34, 37, and 40 years at sampling). The routine
respiration data are shown. These measurements were taken after
trypan-blue staining and a count for the exclusion of the presence
of massive cell death.
(B) Total cellular (light gray bar) and mitochondrial (black bars)
ATP content expressed as relative light unit (RLU) measured in
SPG28, SPG49, and control lymphoblasts.
(C) H2DCFDA fluorescence gives a measure of the concentration
of cytosolic hydrogen peroxide in control cells (white bar) and
in CYP2U1 (light gray bar) and DDHD1 (black bars) mutant cells.
The p values comparing mutant cells to control cells are indicated
above each histogram (Student’s t test). Error bars represent
the SD.
1058 The American Journal of Human Genetics 91, 1051–1064, Decemeasured by the comparison of the level of mitochondrial
TOM20, was detected in lymphoblasts of affected cases
(data not shown), suggesting that the observed reduction
in mitochondrial energy fluxes results from a functional
oxidative-phosphorylation-system alteration caused by
mutations in SPG28/DDHD1 and SPG49/CYP2U1.
Reduced oxygen consumption could be confirmed in
skin fibroblasts of an SPG49-affected individual compared
to controls (Figure S8A). Given that respiration originates
from the activity of the respiratory chain and the consecu-
tive buildup of an electrochemical gradient of protons, we
measured those two parameters. As seen in Figure S8B,
the transmembrane electric potential (Dc) measured with
TMRM was 30% lower in the SPG49 fibroblasts than in
the three controls (respective p values of 0.0011, 0.0010,
and 0.0033). To take into account the nonspecific fluores-
cence due to TMRM (data not shown), we obtained the
same results with the Dc dissipating agent FCCP (uncou-
pler, p-trifluoromethoxy carbonyl cyanide phenyl hydra-
zone). However, the catalytic activities of each of the
respiratory-chain complexes assayed in vitro were not
altered in the SPG49 fibroblasts or in the lymphoblasts
obtained from subjects with SPG28 and SPG49 mutations
(Figure S9). This spectrophotometric assay of complexes
I–IV was performed in experimental conditions of a so-
called ‘‘isolated enzyme’’ with mechanical disruption of
mitochondrialmembranes and the addition of excess exog-
enous substrates. In contrast, mitochondrial respiration,
ATP synthesis, and Dc were measured in cells with intact
mitochondrial membranes, so alteration in membrane
properties could be responsible for the observed bioener-
getic failure in cells of affected individuals. Interestingly,
we observed structural abnormalities of the mitochondrial
membrane, given that the mitochondrial network pre-
sented with unusual signs of tubule self-fusions in the
SPG49 fibroblasts. These abnormalities included the pres-
ence of numerous (1) ‘‘donut-like’’ vesicles 800 nm in diam-
eter within the mitochondrial tubules and (2) circular
subnetworks 5 mm in diameter (Figure 4). These features
were observed with either outer-membrane TOM20
labeling (Figure 4) ormitochondrial-matrix dyes such asmi-
totracker (data not shown) or mito-GFP (Figure S10). All
together, our findings indicate mitochondrial-membrane-
organization alteration associated with a reduction of
energy production. Previous studies revealed that such re-
modeling of mitochondrial tubules could influence the
internal diffusion of energy metabolites, the sequestration
and conduction of the electric membrane potential (DJ),
the stability of the respirasome, the efficiency of oxidative
phosphorylation, the diffusion of proteins, or the delivery
of newly synthesized ATP to various cellular areas.33Discussion
We have described a clinicogenetic entity, SPG49, associ-
ated with a wide range of phenotypes from pure tomber 7, 2012
Figure 4. Abnormal Structures in the Mitochondrial Network of SPG49-Affected Skin Fibroblasts
Mitochondrial-network morphology was analyzed by confocal microscopy of skin fibroblasts obtained from control individuals (A) and
from individual HSP1363-IV.1 (B). The images on the right are high magnifications (53 zoomed in) of the images on the left. The mito-
chondrial network was labeled by immunocytochemistry with specific antibodies directed against TOM20, an outer-membrane mito-
chondrial protein, and fluorescence confocal imaging on a Zeiss Vivatome microscope followed. Three-dimensional stacks were
obtained, and the projection images are shown here. We observed two types of abnormal structures on the mitochondrial network of
SPG49 cells: small ‘‘donut-like’’ vesicles (800 nm in diameter) suggestive of self-fused mitochondrial filaments (D) and larger circular
subnetworks (5 mM in diameter) (C). Counting of these two types of abnormal structures was performed on 50 control cells and 50 cells
from the tested subject (right panels). Mean values and p values (Student’s t test) are shown, and error bars represent the SD.complex forms causing a thin corpus callosum and mental
impairment, as in SPG11 and SPG15,34,35 or basal-ganglia
calcification (see GeneReviews in Web Resources). Second,
the identification of the causative mutations in SPG28-
and SPG49-affected families highlights lipid metabolism
as a critical pathway in HSP given that CYP2U1 andThe American JouDDHD1 encode fatty-acid- and/or phospholipid-metabo-
lizing enzymes.
DDHD1 was previously identified as a PA-preferring
phospholipase A1 (PA-PLA1) but is also known to
serve as a substrate for phosphatidylinositol to form
2-arachidonoyl lysophosphatidylinositol.27,36 DDHD1 isrnal of Human Genetics 91, 1051–1064, December 7, 2012 1059
ubiquitously expressed in human tissues such as the brain
and testis, but the physiological role of this enzyme has
not been fully established. DDHD1 orthologs, p125 and
DDHD2 (KIAA0725p), are involved in the maintenance
of the ER and/or Golgi structures.37,38 Therefore, DDHD1
might also be involved in similar functions in the
maintenance of organelle membranes and intracellular
trafficking.
CYP2U1 is one of the oldest identifiable vertebrate cyto-
chrome P450 proteins implicated in u- and u-1 fatty-acid
(C16–C22) hydroxylation.28 In vitro, CYP2U1 is able to
catalyze the hydroxylation of arachidonic acid and related
long-chain fatty acids such as eicosapentaenoic (EPA) and
docosahexaenoic (DHA) acids. Two known metabolites,
19- and 20-hydroxyeicosatetraenoic (HETE) acids, are local
mediators of signal transduction.28,39–41
These two enzymes most likely act in the same
pathway related to phospholipid degradation and fatty-
acid metabolism, which is in agreement with (1) the
coregulation of the expression of DDHD1 and CYP2U1,
specifically in the CNS, (2) the identification of muta-
tions in both genes in affected subjects with relatively
similar clinical presentations, and (3) similar conse-
quences of these mutations for mitochondrial physi-
ology. In addition, other enzymes involving the metabo-
lism of fatty acids and phospholipids have been implicated
in neurodegeneration.8,42–44 PA and phosphatidylinositol,
as well as the bioactive lipids resulting from their
metabolism, modulate membrane properties and play
a role in signal-transduction pathways.45,46 Alterations of
this pathway (Figure 5) in individuals with HSP could
thus have various consequences leading to the observed
phenotypes.
First, phospholipids and fatty acids can serve as precur-
sors of a wide variety of bioactive lipid messengers45,46
that exhibit hormone- or neurotransmitter-like activity
through membrane receptors. Previously, one of the
authors found that the major molecular species of
phosphatidylinositol (PI), 1-stearoyl-2-arachidonoyl PI,
was able to serve as substrate of DDHD1 to generate
2-arachidonoyl lysophosphatidylinositol, a potent agonist
of GPR55,47,48 considered a cannabinoid receptor,49 like
CB1 or CB2.30,50 Arachinonic acid is metabolized to
various eicosanoids through cyclooxygenase and lipoxyge-
nase pathways. CYP2U1 is known to convert arachidonic
acid into 19- and 20-HETE acids, which are known to regu-
late ion channels and neurotransmitter release.28,51,52 In
particular, 20-HETE acid has recently been reported as
a potent activator of the transient receptor potential vanil-
loid 1 (TRPV1) channel. TRPV1 colocalizes with cannabi-
noid receptors CB1 and CB2 in brain and sensory neurons
and seems to be gated by endocannabinoids, such as anan-
damide and N-arachidonoyl dopamine.51,52 Although the
bioactive lipids synthesized by DDHD1 and CYP2U1
have not been shown to act directly on mitochondria,
their action on receptors might mediate their effect, as
has been demonstrated for the CB1 cannabinoid receptors,1060 The American Journal of Human Genetics 91, 1051–1064, Decewhich can regulate mitochondrial respiration and energy
production.53
Second, mitochondrial-membrane lipid composition
is critical for maintaining proper bioenergetic func-
tions,23,54 and the alteration of phospholipid metabolism
has already been shown to impact mitochondrial func-
tions and trigger secondary cellular dysfunction.54–56
Indeed, maintenance of membrane composition, particu-
larly of the mitochondrial membrane, should be critical
for the functions of the long axons of the corticospinal
tracts. The shape of the mitochondrion is also known to
be linked to mitochondrial functions, including respira-
tion, and the dysregulation of the mitochondria dynamics
causes mitochondrial dysfunction.57 PA, a fusogenic phos-
pholipid at the mitochondrion surface, is postulated to
regulate the fusion of mitochondria.56 Overexpression of
mitochondria phospholipase D (MitoPLD) causes contin-
uous giant perinuclear mitochondria, but the reduced
function of MitoPLD causes noncontiguous mitochondrial
fragments. In the present study, the mutation of DDHD1
(SPG28) was shown to cause mitochondrial dysfunction,
including reduced respiration and ATP production. It is
tempting to postulate that the associated mitochondrial
bioenergetic dysfunction might result from the accumula-
tion of PA in mitochondria given that DDHD1 exhibits
PA-degrading activity (PA-PLA1). SPG28 fibroblasts were
not available for exploring this finding, but the abnormal
mitochondrial organization in SPG49 fibroblasts suggests
that the pathway implicated in SPG28 and SPG49 has
a role in this process. Mitochondrial abnormalities could
also result from other, unknown, mechanisms because
the link between altered mitochondrial morphogenesis
and neuronal impairment has already been shown in other
diseases, including other forms of HSP.12,32,58–63 Further-
more, because these results on mitochondrial-network
disorganization were derived from results from one single
fibroblast culture, additional individuals with CYP2U1
and DDHD1 mutations are required for making firm
conclusions.
Lastly, other mechanisms could also contribute to the
disease. Indeed, in numerous conditions of mitochondrial
respiratory impairment, increased reactive oxygen species
(ROS) were observed, as in SPG28 and SPG49 cells. Such
ROS overproduction could play a role in neuronal degener-
ation, as previously suggested for HSP pathophysiology.64
In conclusion, our identification of causative mutations
in two genes demonstrates the importance of combining
systematic gene mapping with large-scale sequencing for
elucidating the molecular basis of HSP. Unraveling the
role of different proteins involved in the same biological
pathway might pave the way for common therapeutic
possibilities for individuals with different gene mutations.
Our results suggest that the membrane itself or membrane-
derived mediators are very important for the neuronal
functions in the corticospinal tracts.
The wide expression of DDHD1 and CYP2U1 sug-
gests that it should be possible to explore metabolicmber 7, 2012
Figure 5. Schematic Representation of the Metabolic Connections between DDHD1 and CYP2U1 Enzymatic Activities
The content of PA on the surface of mitochondria is known to regulate mitochondrial fusion; PA is generated by mitochondrial phos-
pholipase D (MitoPLD) and is further degraded by lipin PA phosphatase. DDHD1 was previously identified as PA-phospholipase A1
(PLA1). The action of DDHD1 might regulate the content of PA on the surface of mitochondria and then be involved in mitochondrial
fusion. The DDHD1mutation causes reduced PA-PLA1 activity, and the resultant increased PA content on the surface of mitochondria
might cause the impairment ofmitochondrial fusion and lead to the dysfunction ofmitochondria. In contrast, phosphatidylinositol (PI)
serves as a substrate of DDHD1 to form 2-arachidonoyl lysophosphatidylinositol (LPI). 2-arachidonoyl LPI is known to act on GPR55,
which is assumed to be a cannabinoid receptor. 2-arachidonoyl LPI might be hydrolyzed by lysophospholipase C into 2-arachidonoyl-
glycerol, which is an endogenous agonist for cannabinoid receptors CB1 and CB2. Arachidonic acid can be released from PI through
phospholipase A2, which includes PLA2G6 (iPLA2 and PNPLA9), and can also be generated from 2-arachidonoyl LPI by neuropathy
target esterase (NTE, PNPLA6) given that this enzyme exhibits high lysophospholipase activity. Arachidonic acid is converted to various
eicosanoids through the cyclooxygenase and lipoxygenase pathways. In addition, arachidonic acid is known to be the preferred
substrate of CYP2U1 to form 19- or 20-HETE acids. Among these, 20-HETE acid is reported as a potent activator of the TRPV1 cation
channel, which is a receptor of endocannabinoids, including anandamide and N-arachidonoyl dopamine. CYP2U1 can also metabolize
esterified forms of arachidonic acid (EPA and DHA). These common arachidonic-acid metabolites can have effects on the endocannabi-
noid system through the CB1, GPR55, and TRPV1 receptors.dysregulation in peripheral tissues, as in SPG5,65 and
develop biomarkers for potential treatment outcome. In
particular, the probable implication of mitochondria in
the pathophysiology of SPG28 and SPG49 could allow
the development of innovative therapeutic strategies
focused on organelle dynamics and bioenergetics, as well
as ROS scavenging.Supplemental Data
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